Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cholinergic therapies for Alzheimer's disease (AD) have been developed following painstaking neuropathological and neurochemical studies. Drugs based upon this approach are in development and it is hoped that these compounds will be of some use as palliative therapy. However, increasing evidence from molecular biology suggests that increasing cholinergic neurotransmission might not only alter cognition but also modify disease progression. The evidence that muscarinic-induced increases in protein kinase C activity favourably alter amyloid precursor protein metabolism and tau phosphorylation is reviewed. A unifying hypothesis of AD pathogenesis brings together plaque and tangle formation, suggesting that cholinergic therapies in development may have far-reaching implications as treatments for AD. (Int J Psych Clin Pract 1997; 1: 15-20).

Original publication




Journal article


Int J Psychiatry Clin Pract

Publication Date





15 - 20


Alzheimer's disease, amyloid.tau, cholinergic neurones, muscarinic agonists